Brokerages expect MEDNAX Inc (NYSE:MD) to announce earnings per share (EPS) of $0.84 for the current fiscal quarter, according to Zacks Investment Research. Eight analysts have made estimates for MEDNAX’s earnings. The lowest EPS estimate is $0.83 and the highest is $0.86. MEDNAX posted earnings of $1.09 per share in the same quarter last year, which suggests a negative year over year growth rate of 22.9%. The business is expected to issue its next quarterly earnings report before the market opens on Wednesday, November 1st.

According to Zacks, analysts expect that MEDNAX will report full-year earnings of $3.29 per share for the current year, with EPS estimates ranging from $3.26 to $3.35. For the next fiscal year, analysts forecast that the firm will post earnings of $3.53 per share, with EPS estimates ranging from $3.33 to $3.62. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that cover MEDNAX.

MEDNAX (NYSE:MD) last released its quarterly earnings results on Friday, July 28th. The company reported $0.85 EPS for the quarter, topping the consensus estimate of $0.81 by $0.04. The business had revenue of $843.00 million during the quarter, compared to analyst estimates of $849.49 million. MEDNAX had a net margin of 7.56% and a return on equity of 9.12%. The company’s quarterly revenue was up 9.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.03 earnings per share.

A number of brokerages have issued reports on MD. BMO Capital Markets began coverage on MEDNAX in a report on Monday, October 16th. They set a “market perform” rating and a $46.00 price objective for the company. Zacks Investment Research raised MEDNAX from a “sell” rating to a “hold” rating in a report on Wednesday, October 11th. Jefferies Group LLC reissued a “hold” rating and set a $46.00 price objective on shares of MEDNAX in a report on Tuesday, October 3rd. KeyCorp raised MEDNAX from a “sector weight” rating to an “overweight” rating and set a $51.00 price objective for the company in a report on Sunday, September 17th. Finally, Robert W. Baird reissued a “hold” rating and set a $47.00 price objective on shares of MEDNAX in a report on Sunday, September 3rd. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $55.44.

TRADEMARK VIOLATION WARNING: “$0.84 EPS Expected for MEDNAX Inc (MD) This Quarter” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at https://www.thecerbatgem.com/2017/10/21/0-84-eps-expected-for-mednax-inc-md-this-quarter.html.

MEDNAX (MD) remained flat at $44.51 during trading on Friday. The stock had a trading volume of 805,620 shares. MEDNAX has a 12 month low of $40.78 and a 12 month high of $72.13. The company has a market capitalization of $4.10 billion, a PE ratio of 14.18 and a beta of 0.37. The firm has a 50 day moving average of $42.97 and a 200-day moving average of $52.21.

In other news, insider John C. Pepia sold 3,000 shares of the firm’s stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $42.85, for a total value of $128,550.00. Following the completion of the sale, the insider now directly owns 35,569 shares in the company, valued at $1,524,131.65. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 2.40% of the company’s stock.

A number of hedge funds have recently made changes to their positions in MD. Pacer Advisors Inc. increased its position in MEDNAX by 8.1% in the second quarter. Pacer Advisors Inc. now owns 1,940 shares of the company’s stock worth $117,000 after purchasing an additional 145 shares during the period. Commonwealth Bank of Australia grew its position in shares of MEDNAX by 15.3% during the 2nd quarter. Commonwealth Bank of Australia now owns 2,205 shares of the company’s stock worth $132,000 after buying an additional 293 shares during the period. Daiwa Securities Group Inc. grew its position in shares of MEDNAX by 20.0% during the 2nd quarter. Daiwa Securities Group Inc. now owns 3,000 shares of the company’s stock worth $181,000 after buying an additional 500 shares during the period. Denali Advisors LLC acquired a new position in shares of MEDNAX during the 3rd quarter worth about $185,000. Finally, Meiji Yasuda Asset Management Co Ltd. acquired a new position in shares of MEDNAX during the 2nd quarter worth about $217,000.

MEDNAX Company Profile

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Get a free copy of the Zacks research report on MEDNAX (MD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for MEDNAX Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX Inc and related stocks with our FREE daily email newsletter.